Drugs / LD-aminopterin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01724931 | Feb 2013 → Sep 2014 | rheumatoid arthritis | Syntrix Biosystems, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LD-aminopterin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01724931 ↗ |
| Known as | L/D-AMT | “N-[4-[[(2,4-diamino-6-pterdinyl)methyl]amino]benzoyl]-L/D-glutamic acid (L/D-AMT) is an investigational drug in phase 1 clinical development that consists of the L-and...” PMID 22653877 ↗ May 2012 |
| Route | Oral | “following oral administration” NCT01724931 ↗ |